Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer

• Published in: Anticancer research 2015-03, Vol.35 (3), p.1791-1796
• Main Authors: Morodomi, Yosuke, Okamoto, Tatsuro, Kohno, Mikihiro, Katsura, Masakazu, Takada, Kazuki, Suzuki, Yuzo, Fujishita, Takatoshi, Kitahara, Hirokazu, Shimamatsu, Shinichiro, Yoshida, Tsukihisa, Tagawa, Tetsuzo, Okano, Shinji, Maehara, Yoshihiko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Female; Fluorouracil - therapeutic use; Gene Rearrangement; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion - genetics; Receptor, Epidermal Growth Factor - genetics
• ISSN: 0250-7005; 1791-7530

Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) gene mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement often have a better prognosis when they are treated with specific inhibitors than when treated with cytotoxic agents. However, the associations between gene mutations and cytotoxic chemosensitivity are still unclear. The objective of the present study was to identify which clinicopathological factors, including genetic mutations, influence chemosensitivity, determined using the succinate dehydrogenase inhibition (SDI) test in patients with NSCLC. The chemosensitivity of tumor tissues from 96 patients with NSCLC who underwent surgical resection was evaluated using the SDI test. In patients with adenocarcinoma, tumors with EGFR gene mutations were significantly more sensitive to 5-fluorouracil (5-FU) than tumors without EGFR gene mutations (p